The (Bourne) Identity of the Bioeconomy

May 12, 2026 | Jim Lane

A man sits in a diner staring out the window at six parked cars. He knows which one probably contains a weapon. He knows the waitress is left-handed. He knows the man at the counter knows how to fight. He knows the exits, the sightlines, the distances, the angles. He knows he can run flat out for half a mile before his hands begin to shake. What he does not know is who he is.

That was the central tension inside The Bourne Identity: capability appearing before identity. A man carrying fragments of coherence without yet possessing the story that explains them. For years, parts of the American bioeconomy have felt a little like that.

Technologies appearing under different names. Companies reorganizing, resurfacing, disappearing, returning. Strange capabilities emerging before the market fully understands what they are for. Fermentation seeking chemistry. Agricultural residues seeking infrastructure. Molecules searching for systems large enough to matter. And perhaps most importantly: companies discovering that survival alone is not enough.

This week, two major announcements suggested that some bioeconomy companies may finally be finding their missing counterpart.

In Augusta, Georgia, Manus broke ground on a Defense Production Act-backed expansion pairing advanced fermentation with continuous-flow pharmaceutical chemistry to secure domestic production of critical medicines.

Meanwhile, NXTClean Fuels and BioVeritas unveiled plans to transform agricultural residues across the Pacific Northwest into sustainable aviation fuel feedstocks compatible with existing HEFA refining infrastructure.

Different sectors. Different molecules. Same emerging pattern. Not solitary technologies trying to become self-contained empires. Capabilities finding alignment.

For decades, the United States has depended heavily on overseas supply chains for many of the critical building blocks behind modern medicine. Few examples are more strategically important than artemisinin, the foundation of frontline malaria therapies recommended worldwide.

Manus has spent years pursuing one of the bioeconomy’s more difficult missions: developing a scalable fermentation pathway for dihydroartemisinic acid, the key precursor to artemisinin. Backed over time by the Gates Foundation and now by the U.S. government, Manus gradually assembled one of the world’s leading bioalternatives scale-up platforms. But the larger story this week was not fermentation alone. It was combination.

Manus announced a strategic collaboration with ArtemiFlow USA, pairing Manus’ biological production system with continuous-flow chemistry capable of converting intermediates into pharmaceutical-grade outputs at industrial scale. Together, the technologies create a rare configuration in American manufacturing: advanced biomanufacturing and cGMP pharmaceutical processing operating under one roof at population scale.

In a sense, the platform found its missing counterpart. Washington noticed.

Through the Department of Health and Human Services’ Defense Production Act Title III program, the federal government committed $32.4 million toward the effort, bringing total federal investment to $47.4 million. The expansion underway in Augusta represents more than another plant groundbreaking. It reflects a broader realization now taking hold across multiple sectors: resilience itself has become strategic infrastructure.

As Manus CEO Ajikumar “Aji” Parayil described it, the project represents “a shift from dependence to capability.” The implications extend well beyond malaria therapies. The same platform could support domestic production pathways for more than 50 essential medicines, including shikimic acid, the starting material behind the antiviral Tamiflu. For years, much of the bioeconomy operated under an implicit assumption that every company needed to become vertically integrated and self-sufficient — master the feedstock, invent the chemistry, finance the scale-up, build the infrastructure, and create the market.

Increasingly, the winners look different. The same pattern is emerging in fuels.

NXTClean Fuels is advancing one of the largest proposed renewable fuels projects in North America at Port Westward, Oregon, targeting production of 50,000 barrels per day — roughly 750 million gallons per year — of Sustainable Aviation Fuel and renewable diesel.

But like much of the SAF industry, the sector faces a structural constraint. The dominant HEFA refining pathway depends heavily on a limited and fiercely contested pool of feedstocks: used cooking oils, animal fats, and similar lipid streams. As global refining capacity has expanded, competition for those inputs has intensified. Enter BioVeritas. Backed by Ara Partners and operating across fuels, chemicals, and biomass conversion pathways, BioVeritas has repeatedly surfaced in different industrial contexts over the years — less a company changing identities than a platform technology searching for systems large enough to absorb its capabilities.

Now it has surfaced beside a potentially transformative SAF platform. Through a newly announced collaboration, NXT and BioVeritas plan to develop Biomass Processing Centers across Oregon, Washington, and Idaho capable of converting agricultural residues into renewable fuel intermediates.

The feedstocks are immense but historically underutilized: wheat straw, rye straw, corn stover, grasses, and other lignocellulosic residues often left to decompose or burned in the field. Millions of tons of stranded biomass may now become strategic feedstock. The strategic importance lies in what BioVeritas produces from them.

Using the proprietary BioVeritas Process, the company converts cellulosic biomass into chemically pure intermediates known as KEYtones. Critically, those intermediates can integrate directly into existing HEFA refining infrastructure. No entirely new refinery ecosystem required. Existing assets can process a dramatically broader and potentially more scalable feedstock base. That changes the geometry of the problem.

As Alan Del Paggio of BioVeritas described it, the collaboration is about “creating a new, durable supply chain from the ground up.” Again, the deeper pattern is not merely technological. It is combinatorial. Biology meeting chemistry. Residues meeting infrastructure. Fermentation meeting flow systems. Existing industrial assets discovering entirely new capabilities through alignment rather than replacement. And geographically, this is no localized story.

Federal biodefense investments are flowing into Georgia. Renewable fuel infrastructure is expanding across the Pacific Northwest. Texas-based companies are forming strategic alliances that may reshape agricultural and aviation supply chains. Behind these projects stand billions of dollars in public and private capital increasingly focused on resilience, domestic production, and industrial durability. The scale is national. The implications are global.

Whether securing medicine supply chains or expanding the feedstock base for low-carbon fuels, these partnerships are addressing the same underlying challenge: how to build systems capable not merely of operating efficiently in stable conditions, but of enduring volatility, scarcity, and disruption.

That may turn out to be the real breakthrough hiding underneath this week’s announcements. Not simply cheaper fuels. Not simply domestic medicines. An improved architecture of industrial resilience.

In an era defined by fragile supply chains, geopolitical instability, and the soaring costs of both disease and energy, resilience is no longer an abstract virtue. It is rapidly becoming the central economic requirement. And increasingly, the companies best positioned to provide it may be the ones that survived long enough to discover not only what they could do — but who, and what, they needed to become.

https://biofuelsdigest.com/the-bourne-identity-of-the-bioeconomy/